ABSTRACT
Introduction: Vitamin D plays a role in the modulation of cytokine release, inflammation, innate and adaptive immunity. It has been frequently discussed that the hyperinflammatory response that causes acute respiratory distress syndrome or other organ damage due to SARS-CoV-2 at the beginning of the pandemic can be modulated by the adequacy of vitamin D. The relationship of vitamin D with many conditions such as mortality, number of intensive care unit stays, disease severity, and organ damage has been investigated, but the information on its effect on secondary infections that occur during the course of the disease is limited. In this study, it was aimed to reveal the relationship of vitamin D with secondary infections that occur during the course of COVID-19 disease. Materials and Methods: Medical records of patients hospitalized in the COVID-19 pandemic service with the diagnosis of COVID-19 were evaluated retrospectively. Results: One hundred eighty-one patients were included in the study. The mean of 25(OH) vitamin D was found to be 18.76 +/- 9.82 ng/mL. When 25-hydroxy vitamin D was compared with gender, disease severity, mortality, need for mechanical ventilation and presence of symptoms, no statistically significant difference was found (p> 0.05). The medical data of the patients during their hospitalization were analyzed and secondary infection was detected in 14.9% (n= 27). When 25-hydroxy vitamin D and the presence of secondary infection were compared, the 25(OH)D vitamin level of those with secondary infection was found to be low and this was found to be statistically significant (p= 0.016). As a result of the evaluation made by ROC analysis, 25-hydroxy vitamin D was found to have a diagnostic value in predicting positive culture results in COVID-19 patients (AUC= 0.771, 95% Confidence Interval= 0.612-0.810, p= 0.003, p< 0.05). Conclusion: While vitamin D continues to be an important topic of discussion in COVID-19 disease due to its effects on the immune system, it should not be forgotten that low vitamin D increases the risk of secondary infection developing in the course of COVID-19 and this may have an impact on prognosis.
ABSTRACT
Introduction: Vitamin D plays a role in the modulation of cytokine release, inflammation, innate and adaptive immunity. It has been frequently discussed that the hyperinflammatory response that causes acute respiratory distress syndrome or other organ damage due to SARS-CoV-2 at the beginning of the pandemic can be modulated by the adequacy of vitamin D. The relationship of vitamin D with many conditions such as mortality, number of intensive care unit stays, disease severity, and organ damage has been investigated, but the information on its effect on secondary infections that occur during the course of the disease is limited. In this study, it was aimed to reveal the relationship of vitamin D with secondary infections that occur during the course of COVID-19 disease. Material(s) and Method(s): Medical records of patients hospitalized in the COVID-19 pandemic service with the diagnosis of COVID-19 were evaluated retrospectively. Result(s): One hundred eighty-one patients were included in the study. The mean of 25(OH) vitamin D was found to be 18.76 +/- 9.82 ng/mL. When 25-hydroxy vitamin D was compared with gender, disease severity, mortality, need for mechanical ventilation and presence of symptoms, no statistically significant difference was found (p> 0.05). The medical data of the patients during their hospitalization were analyzed and secondary infection was detected in 14.9% (n= 27). When 25-hydroxy vitamin D and the presence of secondary infection were compared, the 25(OH)D vitamin level of those with secondary infection was found to be low and this was found to be statistically significant (p= 0.016). As a result of the evaluation made by ROC analysis, 25-hydroxy vitamin D was found to have a diagnostic value in predicting positive culture results in COVID-19 patients (AUC= 0.771, 95% Confidence Interval= 0.612-0.810, p= 0.003, p< 0.05). Conclusion(s): While vitamin D continues to be an important topic of discussion in COVID-19 disease due to its effects on the immune system, it should not be forgotten that low vitamin D increases the risk of secondary infection developing in the course of COVID-19 and this may have an impact on prognosis.Copyright © 2022 Bilimsel Tip Yayinevi. All rights reserved.
ABSTRACT
Introduction: Vitamin D plays a role in the modulation of cytokine release, inflammation, innate and adaptive immunity. It has been frequently discussed that the hyperinflammatory response that causes acute respiratory distress syndrome or other organ damage due to SARS-CoV-2 at the beginning of the pandemic can be modulated by the adequacy of vitamin D. The relationship of vitamin D with many conditions such as mortality, number of intensive care unit stays, disease severity, and organ damage has been investigated, but the information on its effect on secondary infections that occur during the course of the disease is limited. In this study, it was aimed to reveal the relationship of vitamin D with secondary infections that occur during the course of COVID-19 disease. Materials and Methods: Medical records of patients hospitalized in the COVID-19 pandemic service with the diagnosis of COVID-19 were evaluated retrospectively. Results: One hundred eighty-one patients were included in the study. The mean of 25(OH) vitamin D was found to be 18.76 ± 9.82 ng/mL. When 25-hydroxy vitamin D was compared with gender, disease severity, mortality, need for mechanical ventilation and presence of symptoms, no statistically significant difference was found (p> 0.05). The medical data of the patients during their hospitalization were analyzed and secondary infection was detected in 14.9% (n= 27). When 25-hydroxy vitamin D and the presence of secondary infection were compared, the 25(OH)D vitamin level of those with secondary infection was found to be low and this was found to be statistically significant (p= 0.016). As a result of the evaluation made by ROC analysis, 25-hydroxy vitamin D was found to have a diagnostic value in predicting positive culture results in COVID-19 patients (AUC= 0.771, 95% Confidence Interval= 0.612-0.810, p= 0.003, p< 0.05). Conclusion: While vitamin D continues to be an important topic of discussion in COVID-19 disease due to its effects on the immune system, it should not be forgotten that low vitamin D increases the risk of secondary infection developing in the course of COVID-19 and this may have an impact on prognosis.
ABSTRACT
Myalgia, arthralgia, headache, chest pain, back pain, abdominal pain, sore-throat may be present in COVID-19. The purpose of this study is evaluating the frequency, intensity and the regional characteristics of pain related symptoms in hospitalized COVID-19 patients as long as neuropathic pain and its components. In this retrospective study, for the assessment of pain, myalgia, arthralgia, headache, sore-throat, chest pain, back pain and abdominal pain were questioned. Intensity of pain was evaluated by an 11-point Numerical Rating Scale. Neuropathic pain detection was performed by Identification Pain Questionnaire (ID-Pain). The frequency of pain in hospitalized patients was 68.5%. The frequency of COVID-19-related symptoms were 53.4% myalgia, 39.7% arthralgia, 41.1% headache, 21.2% sore-throat, 21.9% chest pain, 28.1% back pain and 15.8% abdominal pain. A statistically significant relationship was observed between headache and hyposmia development (odds ratio= 6.53;95% CI: 3.14-13.60;P<0.001). In neuropathic pain assessment, ID-Pain scores of 6 (4.1%) of patients were found >= 2. For neuropathic pain components, it was observed that hot/burning type was accompanying to pain in 12 (8.2%) of patients while pins and needles type was accompanying in 8 (5.5%) of the patients. In hospitalized COVID-19 patients, myalgia, arthralgia and headache are most frequent pain types. Headache was found to be related with hyposmia. Neuropathic pain or mixed pain with a neuropathic component is not a rare conditi on in COVID-19 disease. Finally, we suggest routine assessment of neuropathic pain in patients with COVID-19. Copyright © 2022, Yuzuncu Yil Universitesi Tip Fakultesi. All rights reserved.
ABSTRACT
Introduction: In late 2019, a new coronavirus disease was detected in Wuhan, China and called COVID-19. Iron metabolism is one of the topics have to be investigated for the development of therapeutic strategies for COVID-19. The aim of this study is to assess changes in traditional biochemical iron status indicators during COVID-19 pneumonia. Materials and methods: A case-control study. Case group was defined as COVID-19 pneumonia with polymerase chain reaction (PCR)-confirmed and the control group consisted of patients with non-COVID-19 pneumonia with culture confirmed. Biomarkers of anemia and iron metabolism, C-reactive protein (CRP), procalcitonin were analyzed. Demographic features, thorax tomography findings, oxygen saturation, development of acute respiratory distress syndrome (ARDS), intensive care unit admission, duration of hospitalization, discharge status (event free survival or death) were evaluated. Results: 205 hospitalized patients with pneumonia were analyzed retrospectively. COVID-19 group was significantly younger than control group. 23 of 106 patients had critical COVID-19 infection. Comorbidity frequency and mortality rate of patients with COVID-19 pneumonia were significantly higher. Hemoglobin (Hb), reticulocyte hemoglobin equivalent (RET-He), iron, transferin saturation (TSAT), CRP, procalcitonin (PCT) and oxygen saturation (SpO2) were significantly lower. Hb, RET-He, iron, TSAT levels significantly correlated to lung aeration loss, hospitalization day and inflamatory markers in COVID-19 pneumonia. Conclusions: The patients with COVID-19 pneumonia had lower iron parameters even they were young. Low RET-He, iron, TSAT may effect the lung aeration loss related to paranchimal infiltrations and mortality of the patients with COVID-19 pneumonia. Our data indicates that iron deficiency parameters associated with longer hospital stays, lower oxygenation, higher CRP and procalsitonin. © 2021 A. CARBONE Editore. All rights reserved.